Ticker: MDT

Medtronic

Healthcare Healthcare Medical - Devices

Price 83.21

Reco Hold Potential 60 Risk 49 Updated 2026-07-25

Official website

Forecast impact

limited

Target +9.4% target fill 91.4%

Reaction D5 -0.01% · D10 -0.75%

Impact Potential 0 · Risk 0 valid until 2026-08-12

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Medtronic is a global leader in medical technology, specializing in the development and manufacturing of devices and therapies to treat chronic diseases. Its core products include cardiovascular devices, diabetes management solutions, and surgical equipment. Major business segments encompass cardiovascular, minimally invasive therapies, restorative therapies, and diabetes. The company generates revenue primarily through the sale of medical devices and related services.

Investment Profile

The investment profile of Medtronic suggests it may be more suitable for dividend-focused investors due to its consistent dividend yield. However, the stock's performance indicates higher risk factors, which may deter growth-oriented investors. Overall, it presents a balanced approach for those seeking income with moderate risk.

Category: Healthcare Sector: Healthcare Industry: Medical - Devices Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader

Fundamental metrics (experimental) Updated: 2026-07-25

EPS (TTM) — earnings per share for the last 12 months, $: 3.75
Revenue QoQ — quarter-over-quarter revenue growth: 8.7%
EPS surprise: 0.6%
20d volatility: 2.0%
Dividend yield: 3.4%
last ex-date: 2026-06-26

AI recommendation changes

Date	Before	After	Reason
2026-07-25	Buy	Hold	Stable dividend, but mixed momentum signals present risks.
2026-07-17	Sell	Buy	Stable dividend, but mixed momentum and performance signals.
2026-07-09	Hold	Sell	Weak momentum and high risk; cautious approach advised.
2026-06-27	Sell	Hold	Stable dividend, but mixed momentum and performance signals.
2026-06-13	Hold	Sell	Mixed performance; cautious outlook amid market pressures.
2026-06-05	Sell	Hold	Strong dividend yield, but mixed momentum signals.
2026-05-08	—	Sell	Weak momentum and high risk overshadow dividend yield.
2026-05-05	Hold	Sell	Компания демонстрирует негативную динамику акций в последние месяцы, но стабильный дивидендный доход и умеренный рост выручки могут поддерживать интерес инвесторов.
2026-03-07	Buy	Hold	Компания Medtronic демонстрирует стабильные финансовые показатели, однако недавние падения цен акций и высокая волатильность указывают на определенные риски. Рекомендуется удерживать акции до более ясных сигналов о восст
2026-02-27	Hold	Buy	Компания Medtronic демонстрирует стабильные финансовые показатели и дивидендную доходность, однако недавние колебания цен и снижение на коротких сроках могут указывать на неопределенность в краткосрочной перспективе.
2026-02-18	Buy	Hold	Компания Medtronic демонстрирует умеренный рост выручки, однако недавние колебания цен акций и высокая волатильность могут указывать на риски. Рекомендуется удерживать акции до более ясных сигналов о восстановлении.
2026-02-08	Hold	Buy	Компания показывает положительную динамику на длительных интервалах, что свидетельствует о стабильности и росте. Несмотря на небольшие колебания в краткосрочной перспективе, долгосрочные тренды указывают на потенциал для
2026-01-30	Buy	Hold	Компания показывает положительную динамику на длительных интервалах, однако недавние колебания цен указывают на неопределенность. Рекомендуется удерживать акции до получения более ясных сигналов.
2026-01-23	Hold	Buy	Компания Medtronic демонстрирует стабильный рост цен на акции за последние месяцы, что указывает на положительные ожидания инвесторов. При этом риск остается на относительно низком уровне, что делает акцию привлекательно

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-07-13	BTIG	Target Raised	90 → 91	83.87
2026-07-06	Evercore ISI	Target Lowered	106 → 105	81.61
2026-06-16	Piper Sandler	Update	— → 85	81.145
2026-06-05	Goldman Sachs	Target Lowered	84 → 83	82.28
2026-06-04	Truist Financial	Target Lowered	95 → 86	81.635
2026-06-04	Bernstein	Target Lowered	— → 97	82.54
2026-06-04	Robert W. Baird	Target Lowered	93 → 85	77.95
2026-06-04	UBS	Target Lowered	90 → 85	77.95
2026-06-04	Jefferies	Target Lowered	— → 88	77.95
2026-06-03	BTIG	Rating Upgraded	— → 90	77.95
2026-06-03	Stifel Nicolaus	Target Lowered	95 → 80	77.95
2026-06-03	Needham	Target Lowered	120 → 101	78.03
2026-06-03	Mizuho Securities	Target Lowered	— → 100	73.75
2026-05-21	Goldman Sachs	Update	— → 84	78.15
2026-04-23	Jefferies	Target Lowered	108 → 95	83.79
2026-04-15	Truist Financial	Target Lowered	103 → 95	86.88
2026-04-13	Mizuho Securities	Target Lowered	125 → 120	86.75
2026-04-09	Evercore ISI	Target Lowered	108 → 106	87.91
2026-03-10	Leerink Partners	Update	— → 119	90.305
2026-03-10	Needham	Update	— → 120	90.21
2026-02-18	Robert W. Baird	Target Lowered	103 → 100	96.41
2026-02-18	Barclays	Target Raised	116 → 118	96.41
2026-02-09	Needham	Rating Upgraded	— → 121	102.9

News Page 1 of 1

Analysts UBS recommend adding low volatility stocks to portfolios, highlighting Yum Brands (YUM), Lockheed Martin (LMT), and McDonald’s (MCD)

07/07/2026, 12:35 PM investing recommendation Analysts: analysts, UBS consumer industrials Stryker Keurig Dr Pepper Medtronic Charles Schwab McDonald's Yum Brands Lockheed Martin Eli Lilly

UBS recommends that investors consider adding low volatility stocks to their portfolios following a strong first half of 2026 for the S&P 500, which rose 9.6%. This strategy aims to mitigate potential market turbulence as investors navigate ongoing economic uncertainties.

Analysts recommend buying dividend stocks like Abbott Laboratories (ABT) and Accenture (ACN) for portfolio income in 2026

06/26/2026, 11:37 AM investing recommendation Analysts: analysts healthcare finance Accenture Intercontinental Exchange Medtronic Abbott Laboratories

In a high-priced stock market, investors are increasingly looking for undervalued dividend stocks that provide income while they wait for potential price appreciation. This strategy is particularly relevant given the current market volatility and inflation concerns.

Analysts BTIG upgraded Medtronic (MDT) to Buy with $90 target price (upside +15%)

06/04/2026, 04:32 AM investing rating_growth Analysts: analysts, BTIG healthcare Medtronic

BTIG has upgraded Medtronic to a buy rating, citing strong growth potential and a favorable valuation compared to peers, suggesting investors could see significant returns.